Randomized trial · people

Larazotide sped gut symptom recovery in children with post-COVID MISC

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This is early evidence from a small trial in children that larazotide, used as an add-on for post-COVID MISC, caused no drug-related side effects and was tied to faster recovery.

Kind
Randomized trial
Studied in
People
Number studied
12
Published
2025
Journal
Sci Transl Med

What they tested

The team tested whether larazotide, given on top of standard care, is safe and helps children recover from multisystem inflammatory syndrome after COVID-19 (MISC).

How the study was done

A phase 2a randomized, double-blind, placebo-controlled trial in 12 children with MISC, median age 5.7 years, who joined while in the hospital. They took larazotide or a placebo (a dummy treatment) four times a day for 3 weeks on top of their usual care, with safety follow-up for 24 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking larazotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

No side effects linked to larazotide were seen. The amount of SARS-CoV-2 spike protein in the blood was correlated with inflammation markers, including interferon-γ (P = 0.004) and interleukin-6 (P < 0.0001), and with gut symptoms on the PedsQL GI symptom score, a questionnaire for children (P = 0.003). Children on larazotide had their gut symptoms settle sooner, cleared spike antigen from the blood faster and got back to their usual activities sooner.

What it doesn’t show

This was a very small, early-stage trial of 12 children, so its safety and benefit results are preliminary. The links between spike levels, inflammation and symptoms are correlations and don't show cause.

The paper

Yonker et al. Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. Sci Transl Med. 2025.

The compound

More studies on Larazotide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking larazotide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo